Drug Trial Radar · NCT07943000
Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 2029
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- University of Vermont Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies. Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental. Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit. Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.
Conditions
- Healthy Volunteers
- Redox Biology
Interventions
ethacrynic acidDrug
Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Peripheral Blood Mononuclear Cell GST ActivityTime frame: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.